BRPI0213165B8 - uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas - Google Patents

uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas

Info

Publication number
BRPI0213165B8
BRPI0213165B8 BRPI0213165A BR0213165A BRPI0213165B8 BR PI0213165 B8 BRPI0213165 B8 BR PI0213165B8 BR PI0213165 A BRPI0213165 A BR PI0213165A BR 0213165 A BR0213165 A BR 0213165A BR PI0213165 B8 BRPI0213165 B8 BR PI0213165B8
Authority
BR
Brazil
Prior art keywords
hydroxyoleic acid
related compounds
drug manufacturing
drugs
manufacture
Prior art date
Application number
BRPI0213165A
Other languages
English (en)
Other versions
BR0213165A (pt
BRPI0213165B1 (pt
Inventor
Vicente Escriba Ruiz Pablo
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of BR0213165A publication Critical patent/BR0213165A/pt
Publication of BRPI0213165B1 publication Critical patent/BRPI0213165B1/pt
Publication of BRPI0213165B8 publication Critical patent/BRPI0213165B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas". a presente invenção refere-se a uso do ácido hidroxioléico e de seus compostos análogos na manufatura de drogas. descreve o uso do ácido hidroxioléico e de seus análogos de fórmula geral i: cooh-chr-(ch~ 2~)~ m~ch=ch-(ch~ 2~)~ n~-ch~ 3~, em que m e n têm, independentemente, um valor de 015 e r pode ser qualquer resíduo com peso molecular abaixo de 200 da, na manufatura de drogas que podem ser usadas no tratamento de câncer, hipertensão, obesidade ou doenças mediadas por alteração da estrutura da membrana e a regulação conseqüente das proteínas g ou dos receptores ligados a elas.
BRPI0213165A 2001-10-11 2002-10-09 uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas BRPI0213165B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200102269 2001-10-11
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.
PCT/ES2002/000475 WO2003030891A1 (es) 2001-10-11 2002-10-09 Utilizacion del acido hidroxioleico y compuestos analogos del mismo en la fabricacion de medicamentos

Publications (3)

Publication Number Publication Date
BR0213165A BR0213165A (pt) 2004-09-14
BRPI0213165B1 BRPI0213165B1 (pt) 2018-01-23
BRPI0213165B8 true BRPI0213165B8 (pt) 2021-05-25

Family

ID=8499164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0213165A BRPI0213165B8 (pt) 2001-10-11 2002-10-09 uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas

Country Status (13)

Country Link
US (3) US20050014831A1 (pt)
EP (1) EP1435235B1 (pt)
JP (1) JP4737931B2 (pt)
CN (3) CN101259121B (pt)
AT (1) ATE322261T1 (pt)
BR (1) BRPI0213165B8 (pt)
CA (1) CA2463348C (pt)
DE (1) DE60210488T2 (pt)
ES (2) ES2186576B1 (pt)
MX (1) MXPA04003255A (pt)
PT (1) PT1435235E (pt)
RU (1) RU2310445C2 (pt)
WO (1) WO2003030891A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
CN101570481B (zh) * 2008-04-30 2012-02-01 上海医药工业研究院 一种多羟基长链脂肪酸及其分离提取方法和在抑制芳香化酶活性中的应用
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
WO2011089265A1 (en) 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
CN101985420B (zh) * 2010-01-29 2014-04-30 苏州润新生物科技有限公司 油酸酯及其制备方法和在制备用于治疗高血压及其并发症的药物中的应用
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
EP2805717A4 (en) * 2012-01-19 2015-06-10 Nippon Suisan Kaisha Ltd APPETITE IN HOUR
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
NZ706067A (en) * 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
JP6348229B2 (ja) * 2014-10-21 2018-06-27 ユニバーシタット デ レス イレス バレアレス ヒドロキシ−トリグリセリドの合成方法、および疾患の予防および処置のためのその使用
US10756968B2 (en) 2015-01-26 2020-08-25 Rapid7, Inc. Network resource management devices methods and systems
CN121041235A (zh) * 2025-11-03 2025-12-02 云南绿A生物工程有限公司 一种藻蓝蛋白软胶囊及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61297A (ja) * 1984-06-12 1986-01-06 日本油脂株式会社 オレイン酸の製造法
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
JPS6344843A (ja) * 1986-08-13 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
CN1118218A (zh) * 1995-03-16 1996-03-13 姜训书 松籽油的制作方法及松籽保健食用油
CN1118228A (zh) * 1995-03-16 1996-03-13 姜训书 松籽果酱
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
DE69626927T2 (de) * 1995-10-30 2003-11-20 Oleoyl-Estrone Developments, S.I. Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
DE19727636C1 (de) * 1997-06-28 1998-11-19 Rwe Dea Ag Verfahren zur Herstellung von 2-Alkylcarbonsäuren
CN1212867A (zh) * 1997-09-29 1999-04-07 宋凤亭 防治心脑血管疾病的组合物
ES2198661T3 (es) * 1998-01-21 2004-02-01 Fideline Composiciones que contienen feromonas para disminuir el estres, la ansiedad y la agresividad en los cerdos.
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
WO2002051406A1 (en) * 2000-12-23 2002-07-04 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
DE10130491A1 (de) * 2001-06-25 2003-04-17 Heirler Horst Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas

Also Published As

Publication number Publication date
CA2463348C (en) 2011-04-05
JP2005527479A (ja) 2005-09-15
BR0213165A (pt) 2004-09-14
CN101259121B (zh) 2011-04-06
ES2186576A1 (es) 2003-05-01
US20110136906A1 (en) 2011-06-09
WO2003030891A1 (es) 2003-04-17
RU2004114229A (ru) 2005-04-20
US20090082446A1 (en) 2009-03-26
US20050014831A1 (en) 2005-01-20
ES2261752T3 (es) 2006-11-16
CN100471492C (zh) 2009-03-25
US7851507B2 (en) 2010-12-14
DE60210488D1 (de) 2006-05-18
BRPI0213165B1 (pt) 2018-01-23
CN101259122B (zh) 2011-04-06
ATE322261T1 (de) 2006-04-15
CA2463348A1 (en) 2003-04-17
CN101259121A (zh) 2008-09-10
JP4737931B2 (ja) 2011-08-03
EP1435235A1 (en) 2004-07-07
DE60210488T2 (de) 2006-12-14
EP1435235B1 (en) 2006-04-05
RU2310445C2 (ru) 2007-11-20
US8778995B2 (en) 2014-07-15
PT1435235E (pt) 2006-08-31
ES2186576B1 (es) 2004-09-16
MXPA04003255A (es) 2005-01-25
CN1688302A (zh) 2005-10-26
CN101259122A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
BRPI0213165B8 (pt) uso de ácido hidroxioléico e compostos relacionados na manufatura de drogas
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
ATE478685T1 (de) Prodrugs mit neuen biospaltbaren verbindern
CR8659A (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
SE9903544D0 (sv) Novel compounds
DK1003504T3 (da) Indolderivater og deres anvendelse som PCP-1-antagonister
EP1489077A4 (en) 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
ATE469161T1 (de) Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
WO2003028641A3 (en) Mch receptor antagonists
ATE427932T1 (de) 11beta-hsd1-inhibitoren
UA102236C2 (uk) Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування
EA200500054A1 (ru) Новые соединения, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
SE0302116D0 (sv) Novel compounds
BRPI0415020A (pt) dissulfeto, sulfeto, sulfóxido e derivados de sulfona de açúcares cìclicos e usos dos mesmos
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
EP2535329A3 (en) Spiro-piperidine derivatives
EP2202222A3 (en) Indene derivatives, their preparation and use as medicaments
UY29244A1 (es) Combinaciones medicas
AU2003274686A1 (en) Inhibitors of the gpib -vwf interaction, their preparation and use
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
NO980333L (no) (R)-5-brom-N-(1-etyl-4-metylheksahydro-1H-1,4-diazepin-6-yl)-2-metoksy-6-metylamino-3-pyridinkarboksamid, fremgangsmåte ved fremstilling derav og farmasöytisk sammensetning inneholdende forbindelsen
WO2007010552A3 (en) N- terminal peg conjugate of erythropoietin
ATE524478T1 (de) Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/10/2022